Sitagliptin antidiabetic drugs

Description Results

Adverse events leading to treatment discontinuation 0.96 [0.40; 2.31]

Adverse events leading to treatment discontinuation 0.74 [0.32; 1.71]

Adverse events leading to treatment discontinuation 1.01 [0.39; 2.59]

Adverse events leading to treatment discontinuation 0.00 [0.00; NaN]

Adverse events leading to treatment discontinuation 0.00 [0.00; NaN]

Adverse events leading to treatment discontinuation 3.07 [0.32; 29.15]

Adverse events leading to treatment discontinuation 1.34 [0.60; 2.98]

Adverse events leading to treatment discontinuation 2.74 [0.29; 25.95]

Adverse events leading to treatment discontinuation 0.76 [0.40; 1.44]

Adverse events leading to treatment discontinuation 5.59 [1.26; 24.88]

Adverse events leading to treatment discontinuation 3.87 [0.44; 33.99]

all causes death 1.01 [0.90; 1.14]

CVdeath 1.03 [0.89; 1.19]

fatal and non fatal stroke 0.97 [0.79; 1.19]

fatal and non fatal MI 0.95 [0.81; 1.11]

CV events 0.99 [0.89; 1.10]

sitagliptin 100 or 200 mg dailym (n=-9)

vs.

placebo (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration: 24 weeks

sitagliptin 100 mg daily (n=-9)

vs.

placebo (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

sitagliptin 25 mg or 50 mg or 100 mg dailyi (n=-9)

vs.

placebo (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

sitagliptin 100 mg daily monotherapy (n=-9)

vs.

placebo (n=-9)

double-blind

Sample size: -9/-9

Primary endpoint:

FU duration:

sitagliptin 100 mg (or 200 mg) daily (n=-9)

vs.

placebo (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

sitagliptin 50 mg b.i.d (n=-9)

vs.

placebo (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

sitagliptin 100 dailyily (n=-9)

vs.

metformin 1000 mg or 2000 mg daily;imag (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

sitagliptin 50mg bid (n=-9)

vs.

glipizide 5mg to 20 mg dailyitm (n=-9)

double-blind

Sample size: -9/-9

Primary endpoint:

FU duration: 12 weeks

sitagliptin 100 mg daily (add-on to metformin therapy)j (n=-9)

vs.

placebo (add-on tometformin therapy); (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

sitagliptin 50 mg daily plus metformin 1000 or 2000 mg dailyç$4 (n=-9)

vs.

metformin 1000 or 2000 mg daily (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

sitagliptin 100 mg daily (add-on to ongoing stable doses of glimepiride, alone or in combination with metformin)ocumen (n=-9)

vs.

placebo (add-on to ongoing stable doses of glimepiride, alone or in combination with metformin); (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

sitagliptin 100 mg daily (add-on to metformin therapy)j (n=-9)

vs.

placebo (add-on to metformin therapy); (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

sitagliptin 100 mg daily (add-on to pioglitazone therapy)sl˜ðõØ (n=-9)

vs.

placebo (add-on to pioglitazone therapy); (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

sitagliptin 100 mg daily (add-on to metformin therapy)j (n=-9)

vs.

placebo (add-on to metformin therapy). (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

sitagliptin 100 mg qd (n=507)

vs.

prestudy sulphonylurea (n=514)

open

Parallel groups

Sample size: 507/514

Primary endpoint:

FU duration:

sitagliptin100 mg qd (n=-9)

vs.

pioglitazone 15 mg qd, up-titrated to 30 mg after 6 weeks (n=-9)

double-blind

Sample size: -9/-9

Primary endpoint:

FU duration: 12 weeks

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

once-daily sitagliptin (100 or 50 mg, depending on renal function) (n=-9)

vs.

placebo (n=-9)

double-blind

Sample size: -9/-9

Primary endpoint:

FU duration: 24 weeks

sitagliptin/metformin 50/500 mg bid uptitrated over 4 weeks to achieve maximum doses of sitagliptin/metformin 50/1000 mg bid (n=-9)

vs.

metformin monotherapy (n=-9)

NA

Cross over

Sample size: -9/-9

Primary endpoint:

FU duration:

sitagliptin 100 mg daily (n=516)

vs.

glimepiride (starting dose 1 mg/day and up-titrated, based upon patient's self-monitoring of blood glucose results, to a maximum dose of up to 6 mg/day) (n=519)

double-blind

Parallel groups

Sample size: 516/519

Primary endpoint:

FU duration: 30 weeks

sitagliptin 50 mg once daily monotherapy (n=-9)

vs.

voglibose 0.2 mg thrice daily before meals (n=-9)

double-blind

Sample size: -9/-9

Primary endpoint:

FU duration: 12 weeks

once-daily sitagliptin 100 mg (n=322)

vs.

placebo (n=319)

double-blind

Sample size: 322/319

Primary endpoint:

FU duration:

once-daily sitagliptin 100 mg (n=528)

vs.

twice-daily metformin 1000 mg (n=522)

double-blind

Sample size: 528/522

Primary endpoint:

FU duration: 24 weeks

pioglitazone 30 mg plus sitagliptin 100 mg once a day (n=-9)

vs.

pioglitazone 15 mg plus metformin 850 mg twice a day (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

sitagliptin phosphate, 100 mg daily (n=-9)

vs.

rosiglitazone maleate, 4 mg daily (n=-9)

open

Sample size: -9/-9

Primary endpoint:

FU duration: 16 weeks

sitagliptin 100mg once daily monotherapy (n=-9)

vs.

placebo (n=-9)

double-blind

Sample size: -9/-9

Primary endpoint:

FU duration: 18 weeks

sitagliptin (n=65)

vs.

placebo (n=26)

double-blind

Sample size: 65/26

Primary endpoint:

FU duration: 12 weeks

sitagliptin 100 mg once daily (n=-9)

vs.

placebo (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

sitagliptin 100 mg once daily (n=-9)

vs.

placebo (n=-9)

double-blind

Sample size: -9/-9

Primary endpoint:

FU duration: 24 weeks

sitagliptin phosphate, one 50 mg or one 100 mg tablet (dose dependant on renal function) orally, once daily (n=7332)

vs.

placebo (n=7339)

double-blind

Parallel groups

Sample size: 7332/7339

Primary endpoint: CV-related death, nonfatal MI, nonfatal stroke, or unstable angina requiring hospitalization

FU duration: 3.0 years (median)